{
  "HER2_positive": {
    "stage_1": {
      "primary_treatments": [
        {
          "name": "TH",
          "drugs": ["Paclitaxel", "Trastuzumab"],
          "reasoning": "Standard adjuvant regimen for small, node-negative Stage I HER2-positive breast cancer.",
          "side_effects": [
            "Fatigue",
            "Peripheral neuropathy",
            "Infusion-related reactions",
            "Cardiac dysfunction",
            "Alopecia"
          ]
        }
      ],
      "follow_up": [
        "History and physical examination every 6–12 months for 5 years.",
        "Annual mammography.",
        "Echocardiogram every 3 months during trastuzumab therapy."
      ],
      "contraindications": [
        "Avoid anthracyclines in patients with cardiac dysfunction.",
        "Avoid paclitaxel in severe peripheral neuropathy."
      ],
      "brca_positive": {
        "treatment": {
          "name": "Olaparib",
          "reasoning": "Consider only if high-risk features are present despite Stage I disease."
        }
      }
    },

    "stage_2": {
      "primary_treatments": [
        {
          "name": "TCHP",
          "drugs": ["Docetaxel", "Carboplatin", "Trastuzumab", "Pertuzumab"],
          "reasoning": "Preferred neoadjuvant regimen for Stage II HER2-positive breast cancer.",
          "side_effects": [
            "Myelosuppression",
            "Diarrhea",
            "Fatigue",
            "Cardiac dysfunction",
            "Nausea and vomiting",
            "Infusion-related reactions"
          ]
        }
      ],
      "follow_up": [
        "Clinical exam every 3–6 months.",
        "Annual mammography.",
        "Cardiac monitoring during HER2 therapy."
      ],
      "contraindications": [
        "Avoid anthracyclines in low ejection fraction."
      ]
    }
  }
}
